Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost 1,345% of its total revenue on research according to an analysis.
As part of a series of interviews in partnership with Indegene focusing on the customer experience in pharma, AstraZeneca’s global consumer marketing director Melissa Fellner tells Paul
Shares in AstraZeneca were sharply down this morning after it warned that the hit from the COVID-19 coronavirus could have an impact lasting a few months.
One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
